BOOST Pharma is a biotechnology research company founded in 2019 and headquartered in Copenhagen, Denmark. They have developed a stem cell therapy for the treatment of osteogenesis imperfecta, a debilitating disease. Their therapy uses novel mesenchymal stem cells with high bone-forming capabilities that migrate to the bone of patients, engraft, and start bone formation. By addressing the disease at an early stage, BOOST Pharma aims to greatly enhance the quality of life for patients in later years.